[{"orgOrder":0,"company":"Pharma Two B","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Myung In Pharm Co. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B to Host a Virtual KOL Event on Successful Phase III Study Results of P2B001 in Parkinson\u2019s Disease (PD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson's Disease and Movement Disorders\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharma Two B Announces Merger with Hepion and $11.5M Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Merger","leadProduct":"Pramipexole Dihydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pharma Two B","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Pharma Two.."}]